120 related articles for article (PubMed ID: 17163292)
1. Treatment of stress urinary incontinence with non-animal stabilised hyaluronic acid/dextranomer (NASHA/Dx) gel : An analysis of utility and cost.
Kobelt G; Fianu-Jonasson A
Clin Drug Investig; 2006; 26(10):583-91. PubMed ID: 17163292
[TBL] [Abstract][Full Text] [Related]
2. An open, multicentre study of NASHA/Dx Gel (Zuidex) for the treatment of stress urinary incontinence.
Chapple CR; Haab F; Cervigni M; Dannecker C; Fianu-Jonasson A; Sultan AH
Eur Urol; 2005 Sep; 48(3):488-94. PubMed ID: 15967568
[TBL] [Abstract][Full Text] [Related]
3. Magnetic resonance imaging to evaluate NASHA/Dx gel (Zuidex) for stress urinary incontinence.
Fianu-Jonasson A; Edwall L; Wiberg MK
Int J Clin Pract; 2006 Oct; 60(10):1181-6. PubMed ID: 16981962
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of a novel system (NASHA/Dx copolymer using the Implacer device) for treatment of stress urinary incontinence.
van Kerrebroeck P; ter Meulen F; Larsson G; Farrelly E; Edwall L; Fianu-Jonasson A
Urology; 2004 Aug; 64(2):276-81. PubMed ID: 15302478
[TBL] [Abstract][Full Text] [Related]
5. Three-year cost-effectiveness model for non-animal stabilized hyaluronic acid and dextranomer copolymer compared with sacral nerve stimulation after conservative therapy for the management of fecal incontinence.
Bernstein MA; Purdy CH; Becker A; Magar R
Clin Ther; 2014 Jun; 36(6):890-905.e3. PubMed ID: 24815061
[TBL] [Abstract][Full Text] [Related]
6. Long-term outcome of transurethral injection of hyaluronic acid/dextranomer (NASHA/Dx gel) for the treatment of stress urinary incontinence (SUI).
Lone F; Sultan AH; Thakar R
Int Urogynecol J; 2010 Nov; 21(11):1359-64. PubMed ID: 20571764
[TBL] [Abstract][Full Text] [Related]
7. Canine bladder tissue responses to injectable stabilized non-animal hyaluronic acid/dextranomer (NASHA/Dx) gel.
Olson ME; Hjelm R
Eur J Obstet Gynecol Reprod Biol; 2008 May; 138(1):114-5. PubMed ID: 17482338
[No Abstract] [Full Text] [Related]
8. Intraureteral injection of NASHA/Dx gel under direct ureteroscopic visualization for the treatment of primary high-grade vesicoureteral reflux.
Mattioli G; Guida E; Rossi V; Podestà E; Jasonni V; Ghiggeri GM
J Laparoendosc Adv Surg Tech A; 2012 Oct; 22(8):844-7. PubMed ID: 22989035
[TBL] [Abstract][Full Text] [Related]
9. Long-term efficacy of NASHA Dx injection therapy for treatment of fecal incontinence.
Mellgren A; Matzel KE; Pollack J; Hull T; Bernstein M; Graf W;
Neurogastroenterol Motil; 2014 Aug; 26(8):1087-94. PubMed ID: 24837493
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy of dextranomer in stabilized hyaluronic acid (NASHA/Dx) for treatment of faecal incontinence.
La Torre F; de la Portilla F
Colorectal Dis; 2013 May; 15(5):569-74. PubMed ID: 23374680
[TBL] [Abstract][Full Text] [Related]
11. Submucosal injection of stabilized nonanimal hyaluronic acid with dextranomer: a new treatment option for fecal incontinence.
Danielson J; Karlbom U; Sonesson AC; Wester T; Graf W
Dis Colon Rectum; 2009 Jun; 52(6):1101-6. PubMed ID: 19581853
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, sham-controlled trial.
Graf W; Mellgren A; Matzel KE; Hull T; Johansson C; Bernstein M;
Lancet; 2011 Mar; 377(9770):997-1003. PubMed ID: 21420555
[TBL] [Abstract][Full Text] [Related]
13. Treatment of vesicoureteral reflux in children using stabilized non-animal hyaluronic acid/dextranomer gel (NASHA/DX): a long-term observational study.
Stenberg A; Läckgren G
J Pediatr Urol; 2007 Apr; 3(2):80-5. PubMed ID: 18947708
[TBL] [Abstract][Full Text] [Related]
14. Injectable bulking treatment of persistent fecal incontinence in adult patients after anorectal malformations.
Danielson J; Karlbom U; Wester T; Graf W
J Pediatr Surg; 2020 Mar; 55(3):397-402. PubMed ID: 31493885
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and quality of life 2 years after treatment for faecal incontinence with injectable bulking agents.
Danielson J; Karlbom U; Wester T; Graf W
Tech Coloproctol; 2013 Aug; 17(4):389-95. PubMed ID: 23224913
[TBL] [Abstract][Full Text] [Related]
16. A short- and long-term follow-up study of intersphincteric NASHA Dx implants for fecal incontinence.
Ezra E; Danielsson JM; Graf W
Tech Coloproctol; 2022 Oct; 26(10):813-820. PubMed ID: 35752984
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of dextranomer/hyaluronic acid copolymer for the management of vesicoureteral reflux. 1: substitution for surgical management.
Benoit RM; Peele PB; Docimo SG
J Urol; 2006 Oct; 176(4 Pt 1):1588-92; discussion 1592. PubMed ID: 16952694
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of endoscopic injection of dextranomer/hyaluronic acid copolymer for vesicoureteral reflux.
Kobelt G; Canning DA; Hensle TW; Läckgren G
J Urol; 2003 Apr; 169(4):1480-4; discdussion 1484-5. PubMed ID: 12629396
[TBL] [Abstract][Full Text] [Related]
19. Identifying factors associated with clinical success in patients treated with NASHA(®)/Dx injection for fecal incontinence.
Franklin H; Barrett AC; Wolf R
Clin Exp Gastroenterol; 2016; 9():41-7. PubMed ID: 27042136
[TBL] [Abstract][Full Text] [Related]
20. Periurethral granuloma following injection with dextranomer/hyaluronic acid copolymer for stress urinary incontinence.
Castillo-Vico MT; Checa-Vizcaíno MA; Payà-Panadés A; Rueda-García C; Carreras-Collado R
Int Urogynecol J Pelvic Floor Dysfunct; 2007 Jan; 18(1):95-7. PubMed ID: 16328113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
